SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease: Jigsaw Falling Into Place
- PMID: 37164524
- DOI: 10.1016/j.jacc.2023.03.389
SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease: Jigsaw Falling Into Place
Keywords: SGLT2 inhibitors; chronic kidney disease; heart failure; prognosis.
Conflict of interest statement
Funding Support and Author Disclosures Dr Kristensen’s institution has received speaker fees from AstraZeneca; and has been on the advisory board for Bayer, outside the submitted work. Dr Jensen has received grants from The Danish Heart Foundation; has received personal fees for scientific advisory board membership from AstraZeneca; and has received fees from scientific advisory board and participation in the KARDINAL study from Boehringer Ingelheim, all outside the submitted work. Dr Schou has received personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, and Novo Nordisk, outside of the submitted work.
Comment on
-
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.J Am Coll Cardiol. 2023 May 16;81(19):1902-1914. doi: 10.1016/j.jacc.2023.03.390. J Am Coll Cardiol. 2023. PMID: 37164523
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources